Top Story Today
Merck KGaA Spent $11.3 Billion on Biotech's Most Important Company You've Never Heard Of
Every biotech lab uses Bio-Techne's products, and now Merck KGaA owns the company. The German pharma giant is paying $73 per share in cash (a 36% premium) for the Minneapolis-based maker of proteins, antibodies, and reagents that underpin modern drug discovery. It's the company's biggest acquisition since Sigma-Aldrich in 2015. New CEO Kai Beckmann is betting that owning the infrastructure of biotech research beats chasing blockbuster drugs. The post-COVID valuation hangover in life sciences tools gave Merck a window, and it climbed through.
Why it matters: This deal accelerates a massive consolidation wave in life sciences tools, where Thermo Fisher, Danaher, and now Merck KGaA are racing to control the essential supplies every drug company depends on. If your lab buys reagents, your pricing dynamics just changed.
Read more →Deals and M&A
Vertex Bets $10 Billion It Can Master a Fifth Disease
Vertex is paying $85 per share (a 102% premium) for Crinetics Pharmaceuticals, its largest acquisition ever. The deal brings in Palsonify, the first oral pill for the rare hormonal disorder acromegaly, plus a Phase 3 candidate for congenital adrenal hyperplasia. Vertex projects more than $5 billion in combined peak sales from the assets, establishing endocrinology as its fifth therapeutic pillar beyond cystic fibrosis.
Read more →AstraZeneca Pays $200M Upfront for a Chinese Lung Drug That Might Outperform Merck's $10B Bet
AstraZeneca licensed TQC3721, a dual PDE3/4 inhibitor for COPD, from Chia Tai Tianqing for $200 million upfront and up to $1.9 billion more. The inhaled drug reportedly shows stronger activity than ensifentrine, the molecule Merck paid roughly $10 billion for. It's the latest sign that China's biopharma pipeline has become Big Pharma's favorite shopping aisle.
Read more →Hansoh Found a Backdoor Into Wall Street
Chinese pharma giant Hansoh created a U.S. subsidiary called Avere, loaded it with $320 million and an oral IL-23 drug, and reverse-merged it into Nasdaq-listed NextCure. Legacy NextCure shareholders keep just 1.2% of the combined company. A Phase 2b psoriasis trial is planned for early 2027, targeting the same market dominated by injectable blockbusters Skyrizi and Tremfya.
Read more →The Biotech Rescue Deal That Needed a Flowchart
Jasper Therapeutics was six months from running out of cash. Instead of folding, it engineered a three-party deal: Kira Pharmaceuticals merges in with $132 million in rescue financing, while Kira's anti-C5a antibody gets licensed out to Mirador Therapeutics. Legacy Jasper shareholders end up with just 6.7% of the combined company, plus contingent value rights worth up to $30 million.
Read more →Clinical and Science
Roche Walked Away From Huntington's. The Biggest Pharma Backer Just Left the Building.
After a decade of work, Roche killed both of its Huntington's gene-silencing programs. Tominersen lowered the toxic protein but patients didn't improve; backup drug RG6496 couldn't be dosed chronically. With 41,000 symptomatic Americans and no approved disease-modifying treatment, the field's best-funded effort is over. UniQure's one-time gene therapy AMT-130 is now the most advanced hope left.
Read more →A $200 Blood Draw That Could Replace a $5,000 Brain Scan
Eli Lilly's P-tau217 blood test matched amyloid PET scan accuracy for detecting Alzheimer's pathology in people with no symptoms. At roughly $200 per draw versus $3,000 for a PET scan, economic models show a blood-first screening strategy catches more patients at lower cost. About 20% of results still land in an indeterminate gray zone, but the trajectory is clear: Alzheimer's diagnosis is moving from the imaging suite to the blood lab.
Read more →A Single Spinal Injection Silenced a Disease Gene for Months
Chinese biotech Ractigen published Nature Medicine data showing its RNA drug RAG-17 cut the SOD1 protein by up to 69% in ALS patients after a single spinal injection, with effects lasting months. Plasma neurofilament levels (a marker of nerve damage) dropped up to 81%. The delivery platform, called SCAD, could unlock RNA therapies for a whole category of brain diseases beyond ALS.
Read more →Regulatory and Market Access
Wegovy Just Became a Liver Drug in India
India approved Wegovy for MASH (fatty liver disease), where roughly 39% of adults have MASLD (fatty liver disease broadly) and few drugs had been approved to treat the more severe MASH subset. The approval, based on the ESSENCE trial showing 63% inflammation resolution versus 34% on placebo, gives Novo Nordisk a three-indication semaglutide franchise in one of the world's largest pharma markets. The company is targeting $1 billion in cumulative Indian Wegovy sales over 5–7 years.
Read more →